

AMENDMENTS TO THE CLAIMS:

Please amend the claims as follows:

Claims 1-16. (Canceled)

17. (Currently Amended) A method for treating a kidney cancer comprising the administration to a subject of an effective dose of a PTHrP antagonist for inhibiting or decreasing a tumor growth or a pharmaceutical composition containing it, said PTHrP antagonist being an anti-PTHrP [[(34-53)]] antibody that binds amino acids 34-53 of PTHrP.

18. (Previously Presented) Method according to claim 17, wherein said subject is a human subject.

19. (Previously Presented) Method according to claim 17, wherein said kidney cancer is selected from the group consisting of papillary carcinoma (chromophiles), chromophobe cell carcinoma, Bellini carcinoma and unclassified renal cell carcinomas.

20. (Previously Presented) Method according to claim 19, wherein said kidney cancer is clear cell carcinoma (CCC).

Claims 21-22. (Cancelled)

23. (Previously Presented) Method according to claim 17, wherein the kidney cancer is a solid malignant tumour.

24. (Previously Presented) Method according to claim 17, wherein the PTHrP antagonist is a compound binding the PTHrP receptor and inhibiting partially or totally a binding of PTHrP to its receptor.

25. (Previously Presented) Method according to claim 24, wherein the PTHrP antagonist is a PTHrP receptor antagonist.

26. (Previously Presented) Method according to claim 25, wherein the PTHrP antagonist is a PTHrP competitive antagonist.

Claims 27-30. (Cancelled)

31. (Previously Presented) Method according to claim 17, wherein the PTHrP antagonist is a compound binding a ligand of the PTHrP receptor, and inhibiting partially or totally a binding of PTHrP to its receptor.

Claim 32. (Cancelled)

33. (Previously Presented) Method according to claim 17, wherein the PTHrP antagonist is a humanised anti-PTHrP antibody.

34. (Previously Presented) Method according to claim 17, wherein the anti-PTHrP antibody is selected from a humanised antibody, a human antibody, a chimeric antibody, an antibody obtained from a hybridoma and a fragment thereof and a modified form of said fragment.

35. (Previously Presented) Method according to claim 17, wherein the anti-PTHrP antibody is a polyclonal or monoclonal antibody.

Claims 36-52. (Cancelled)